Interventional Oncology Devices – Market Insights – Europe

The European interventional oncology device market will see modest growth through 2033, driven by increasing incidence and prevalence rates of cancer, cost-effectiveness of ablation and embolization devices compared to surgery, improved reimbursement, changing guidelines, launch of innovative products, increasing popularity of minimally invasive surgeries, and growing physician acceptance of interventional oncology procedures. However, growth in this market will be hindered by mixed clinical data, increasing-price competition, and ongoing cost constraints in the region.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for interventional oncology devices in Europe from 2019 to 2033.

The ablation device market is dominated by microwave ablation; however, new technologies are increasingly being used.

What is driving growth within the microwave ablation device segment?

How has the adoption of cryoablation changed the market dynamics in the microwave and RF ablation device segments?

How are IRE devices performing in the market? What has driven or limited their growth in the market?

What are the strategies employed by key competitors to position themselves in this market, and what challenges do they face?

Which major clinical trials are being conducted, and how will they impact the interventional oncology device market?

Ablation therapy procedures will continue to grow for the liver, kidney, and lung cancer indications.

How does resection compete against the ablation techniques? What role is being played by guidelines in the adoption of ablation therapies over resection?

How is RF competing against the Microwave ablation devices?

What are the advantages and disadvantages of each type of ablation device offered by competitors, and how do these differences affect adoption for different indications?

How will growth vary across different ablation device categories?

DEBs and radioembolization spheres are seeing increasing adoption.

How will the market growth vary across different embolization device categories?

What is the adoption outlook for different embolization devices, and what factors will affect the penetration of these technologies over the forecast period?

What impact will clinical guidance and clinical trials have on the adoption of DEBs and radioembolization spheres?

How are radioembolization spheres being adopted by physicians in the European market? How are Holmium-166 radioembolization spheres performing in comparison to Y90 radioembolization spheres?